IPO Issue Details
Issue Price / Price Band₹123 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size1,000 Shares per Lot
Total Issue Size22,41,000 shares (aggregating up to ₹27.56 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital
Exchange / PlatformBSE SME
IPO TypeSME
Subscription OpenWed, 09 Jul 2025
Subscription CloseFri, 11 Jul 2025
Anchor AllotmentTue, 08 Jul 2025
Basis of AllotmentMon, 14 Jul 2025
Initiation of RefundsTue, 15 Jul 2025
Credit of Shares to DematTue, 15 Jul 2025
Listing DateWed, 16 Jul 2025
UPI Mandate Deadline2025-07-11
Application & Investment Details
Retail — Min (2 Lots)₹2,46,000 — 2000 shares
Retail — Max (13 Lots)₹1,599,000 (13 Lots)
HNI — Min (3 Lots)₹3,69,000 — 3000 shares
EPS (Pre-IPO)₹6.90
EPS (Post-IPO)₹9.32
P/E Ratio (Pre-IPO)17.83x
P/E Ratio (Post-IPO)13.2x
Net Offer to Public21,28,000 shares (aggregating up to ₹26.17 Cr)
Reserved for Market Maker1,13,000 shares (aggregating up to ₹1.39 Cr)
Pre-IPO Promoter Holding62,71,360 shares
Post-IPO Promoter Holding85,12,360 shares
About Asston Pharmaceuticals Ltd.
Incorporated in 2019, Asston Pharmaceuticals Limited is engaged in the business of pharmaceuticals, specializing in exporting healthcare products globally.The company offers a diverse range of products, including tablets, capsules, sachets, and syrups. Its product portfolio encompasses various therapeutic categories, such as analgesics, antibiotics, antifungals, vitamins, and more.The company manufactures pharmaceutical products for direct sales and also on a contract manufacturing or loan license basis, primarily working on a principle-to-principle approach with various marketers.The company is FDA certified by both Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing.Products:Albendazole USP 400 mg: Albendazole USP 400 mg refers to a higher dosage of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication that is used to treat various parasitic worm infections.Diclofenac 100 mg: Diclofenac 100 mg refers to a specific dosage of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two commonly used over-the-counter medications, often used to relieve pain and reduce fever.Ferrovit Syrup: To treat vitamin and mineral deficiencies.As of 3 July 2025, the company has 46 Permanent employees and 6 contractual employees in various departments.Competitive Strengths:Formulation ExpertiseExperienced PromotersWide range of ProductsStrategic LocationSkilled Workforce
Objects of the Issue
Asston Pharmaceuticals Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
1 Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit
6.00
2
2 Funding the incremental working capital requirements of the Company
13.00
3
3 Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
1.00
4
4 General Corporate Purposes
3.95
Shareholding & Lock-in
Pre-IPO Promoter Holding
62,71,360 shares
Post-IPO Promoter Holding
85,12,360 shares